Related Experiment Video
Updated: May 15, 2025
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Unraveling the Specific Recognition Between PD-L1 and Engineered CLP002 Functionalized Gold Nanostructures: MD
Micaela Giannetti1, Marina Gobbo2, Lucio Litti2
1Department of Chemical Science and Technologies, University of Rome "Tor Vergata", Via della Ricerca Scientifica, 00133 Rome, Italy.
Insights
Researchers used molecular dynamics simulations to understand how peptides bind to PD-L1, a protein often overexpressed in cancer cells. This study highlights the crucial role of linkers in peptide-nanostructure interactions for cancer recognition.
Area of Science:
- Biophysics
- Nanotechnology
- Cancer Biology
Background:
- Programmed cell death ligand-1 (PD-L1) is a protein on regulatory cells that suppresses immune responses by binding to PD-1 on immune cells.
- Tumor cells often overexpress PD-L1 to evade immune detection, making PD-L1 a target for cancer therapy and localization.
- Functionalized peptides can be used to detect PD-L1, with peptide CLP002 showing promise when bound to gold nanostructures for breast cancer cell recognition.
Purpose of the Study:
- To characterize the molecular interactions between PD-L1 and peptide-functionalized nanostructures.
- To investigate the role of linker molecules in the binding affinity and specificity of peptide-PD-L1 interactions.
- To provide an in silico method for evaluating parameters crucial for PD-L1 binding in cancer recognition.
Main Methods:
- Molecular dynamics (MDs) simulations were employed to study peptide monolayers on gold surfaces.
- Simulations were conducted in the presence and absence of PD-L1 to analyze binding characteristics.
- The interaction of the specific peptide CLP002 and a scrambled version was compared.
Main Results:
- The study elucidated the molecular-level interactions between PD-L1 and peptide-functionalized gold nanostructures.
- The nature of the linker significantly influences the binding efficiency and stability of the peptide-PD-L1 complex.
- A scrambled peptide sequence showed markedly reduced activity compared to CLP002, underscoring sequence-specific binding.
Conclusions:
- Molecular dynamics simulations are effective for understanding peptide-PD-L1 interactions at the molecular level.
- Linker design is a critical factor for optimizing peptide-based nanostructures for PD-L1 detection.
- These findings pave the way for in silico design and optimization of diagnostic tools for cancer recognition.
Abstract:
PD-L1 (programmed cell death ligand-1) is a protein located on the surface of regulatory cells. It has an immunosuppressive role as it binds specifically to the protein programmed cell death-1 (PD-1), a checkpoint glycoprotein, present on the surface of immune cells such as T and B lymphocytes. Many tumor cells block the immune response by overexpressing PD-L1 on their surface; therefore, targeting PD-L1 represents a powerful strategy that allows tumor localization. To determine the presence of PD-L1 in cells, the use of ad hoc functionalized peptides that bind to PD-L1 can be exploited. One of them is the peptide CLP002 (Trp-His-Arg-Ser-Tyr-Tyr-Thr-Trp-Asn-Leu-Asn-Thr), which, bound to surface-enhanced Raman scattering (SERS) gold nanostructures via a suitable linker, was shown to be highly effective in recognizing MDA-MB-231 breast cancer cells and, importantly, this recognition can be measured by SERS experiments. To characterize, on a molecular scale, the interaction between PD-L1 and peptide functionalized nanostructures, we performed molecular dynamics (MDs) simulations, studying the features of peptide monolayers bound on gold surfaces in the absence and presence of PD-L1. The results obtained allow us to explain why the nature of the linker plays a fundamental role in the binding and why a peptide carrying the same amino acids as CPL002 but with a different sequence (scrambled) is much less active than CLP002. These results open the way to an in silico evaluation of the key parameters that regulate the binding of PD-L1 useful for cancer recognition.
